IP Library Granted Patent US 9,993,576
Granted Patent B2
US 9,993,576 · App. 15/670,284 · Granted Jun 12, 2018

Cement products and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,576
App. No.
15/670,284
Granted
Jun 12, 2018
Kind
B2
Abstract

Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.

Claims (25)

1. An orthopedic cement product comprising:

a first component comprising a polymerizable resin that comprises two or more acrylate groups;

a second component comprising a compound selected from the group consisting of putrescine (1,4-diaminobutane), spermidine, and spermine; and

a bioceramic filler;

wherein the first component and second component are capable of reacting with each other in a polymerization reaction to produce an orthopedic or dental cement,

wherein when the first component and second component are reacted together in a polymerization reaction at room temperature and allowed to set at about 37° C., the reaction does not exceed a maximum temperature of 60° C. for a period of one minute; and

wherein the cement product after setting has a compressive strength of about 20 MPa to about 250 MPa.

2. The cement product of claim 1 , wherein the first component comprises a compound selected from the group consisting of bisphenol A glycerolate di(meth)acrylate, non-alkoxylated trimethylpropane tri(meth)acrylate (TMPT(M)A), ethoxylated(15) TMPT(M)A, ethoxylated (9) TMPT(M)A, ethoxylated (6) TMPTA, ethoxylated (3) TMPTA, propoxylated (3) TMPT(M)A, propoxylated (6) TMPT(M)A, propoxylated (5) glycerol ethoxylated bisphenol-A-triacrylate, ethoxylated (2) bisphenol A diacrylate (E(2)Bis)A), ethoxylated(4) bisphenol A diacrylate (E(4)BisDA), trimethylolpropane benzoate diacrylate, pentaerythritol triacrylate, pentaerythritoltetraacrylate, butanedioldiacrylate, hexanedioldiacrylate and mixtures thereof.

3. The cement product of claim 1 , wherein the first component comprises trimethylolpropane triacrylate.

4. The cement product of claim 1 , wherein the first component comprises non-alkoxylated pentaerythritol triacrylate.

5. The cement product of claim 1 , wherein the first component comprises E(2)Bis)A, E(4)BisDA, trimethylolpropane benzoate diacrylate, 1,4-butandioldiacrylate, 1,3-butanedioldiacrylate, 1,6-hexanediol diacrylate, or a mixture thereof.

6. The cement product of claim 1 , wherein the second component further comprises one or more synthetic polyamine selected from the group consisting of 2-methyl-1,5-pentamethylenediamine, 2-ethyl-1,3-trimethylenediamine, N-(3-Aminopropyl)-1,3-propanediamine, diethylenetriamine (DETA), triethylenetetramine (TETA), and polyethyleneimine (PEI).

7. The cement product of claim 1 , wherein

the first component comprises trimethylolpropane triacrylate, and

the second component further comprises 2-methyl-1,5-pentamethylenediamine.

8. The cement product of claim 7 , wherein

the first component comprises bisphenol A diglycidyl ether 33-67% w/w, trimethylolpropane triacrylate 33-67% w/w, and, optionally, trimethylolpropane benzoate diacrylate 0-33% w/w; and

the second component comprises a mixture of spermidine in an amount of at least 33% w/w and 2-methyl-1,5-pentamethylenediamine in an amount up to 67% w/w.

9. The cement product of claim 1 , wherein

the first component comprises trimethylolpropane triacrylate; and

the second component further comprises a polyamine selected from the group consisting of 2-methyl-1,5-pentamethylenediamine, 2-ethyl-1,3-trimethylenediamine, or a combination thereof.

10. The cement product of claim 9 , wherein

the first component comprises sorbitol polyglycidyl ether 0-40% w/w, trimethylolpropane triacrylate in an amount up to 30% w/w, and 1,4-butanediol 0-20% w/w such that the weight percent of sorbitol polyglycidyl ether, the weight percent of trimethylolpropane triacrylate, and the weight percent of 1,4-butanediol total 100% w/w; and

the second component comprises spermidine 20-100% w/w and a second polyamine compound selected from the group consisting of 2-methyl-1,5-pentamethylenediamine and 2-ethyl-1,3-trimethylenediamine, in an amount up to 80% w/w.

11. The cement product of claim 1 , wherein the bioceramic filler comprises tricalcium phosphate, hydroxyapatite, calcium phosphate, or a combination thereof.

Assignments (12)
SECURITY INTEREST Recorded Aug 11, 2024
From: XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.; SURGALIGN SPV, INC.; XTANT MEDICAL HOLDINGS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 068539/0665 →
SECURITY INTEREST Recorded Aug 11, 2024
From: XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.; SURGALIGN SPV, INC.; XTANT MEDICAL HOLDINGS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068539/0492 →
SECURITY AGREEMENT SUPPLEMENT (TERM) Recorded Dec 22, 2023
From: XTANT MEDICAL HOLDINGS, INC.; XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 066095/0635 →
SECURITY AGREEMENT SUPPLEMENT (REVOLVING) Recorded Dec 22, 2023
From: XTANT MEDICAL HOLDINGS, INC.; XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 066095/0652 →
MERGER Recorded Oct 19, 2023
From: PIONEER SURGICAL TECHNOLOGY, INC.
To: PIONEER SURGICAL TECHNOLOGY NEWCO, INC.
Reel/Frame 065287/0641 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2023
From: PIONEER SURGICAL TECHNOLOGY NEWCO, INC.
To: XTANT MEDICAL HOLDINGS, INC.
Reel/Frame 065218/0590 →
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2020
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
Reel/Frame 053260/0398 →
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2020
From: ARES CAPITAL CORPORATION, AS AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 053257/0652 →
SECURITY INTEREST Recorded Mar 8, 2019
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 048543/0505 →
SECURITY INTEREST Recorded Jun 6, 2018
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS THE ADMINISTRATIVE AGENT
Reel/Frame 046303/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2017
From: SCHLOSSBERG, BRIAN M
To: PIONEER SURGICAL TECHNOLOGY, INC.
Reel/Frame 043266/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2017
From: LIN, JUCHUI RAY; AHN, EDWARD S
To: PIONEER SURGICAL TECHNOLOGY, INC.
Reel/Frame 043266/0758 →